<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00959556</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000633531</org_study_id>
    <secondary_id>COL-GENEOM</secondary_id>
    <secondary_id>COL-IDRCB-2007-A00908-45</secondary_id>
    <secondary_id>COL-2007-08</secondary_id>
    <secondary_id>INCA-RECF0635</secondary_id>
    <nct_id>NCT00959556</nct_id>
  </id_info>
  <brief_title>Study of Blood Samples in Patients With Breast Cancer</brief_title>
  <official_title>Search for Genetic Factors Predictive of Response to Chemotherapy in Patients With or Who Has a Mammary Adenocarcinoma in Neo-adjuvant or Metastatic Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying the genes expressed in samples of blood from patients with cancer may
      help doctors identify biomarkers related to cancer. It may also help doctors predict how
      patients will respond to chemotherapy.

      PURPOSE: This clinical trial is studying blood samples in patients with breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Identify constitutional gene variants associated with a change in response.

      OUTLINE: Blood samples are collected periodically for analysis of genetic factors.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2007</start_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Histologic complete response (Chevallier and Sataloff) or tumor response (RECIST)</measure>
  </primary_outcome>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed breast carcinoma

          -  Received first-line chemotherapy (in neoadjuvant or metastatic setting) comprising
             anthracyclines and/or taxanes, including for a second primary cancer

          -  Patient agrees to conservative surgery

          -  Hormone receptor status not specified

        PATIENT CHARACTERISTICS:

          -  Menopausal status not specified

          -  No contraindication for chemotherapy comprising anthracyclines and/or taxanes

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior adjuvant therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques Bonneterre, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Bonneterre, MD, PhD</last_name>
      <phone>33-3-20-29-5959</phone>
      <email>j.bonneterre@o-lambret.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2009</study_first_submitted>
  <study_first_submitted_qc>August 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2009</study_first_posted>
  <last_update_submitted>January 7, 2011</last_update_submitted>
  <last_update_submitted_qc>January 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2011</last_update_posted>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IA breast cancer</keyword>
  <keyword>stage IB breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

